ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0588

Feast or Famine? An Institutional Assessment of Hydroxychloroquine Screening Practices

Alanna James1, Kelli Kam1, Vaneet Sandhu2 and Christina Downey3, 1Loma Linda University Health, Loma Linda, CA, 2Loma Linda University, Loma Linda, CA, 3Loma Linda University Medical Center, Redlands, CA

Meeting: ACR Convergence 2020

Keywords: Clinical practice guidelines, Cost-Effectiveness, Drug toxicity, practice guidelines, quality of care

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: Health Services Research Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Hydroxychloroquine (HCQ) is a generally safe and widely used rheumatologic drug. Maculopathy is an adverse effect in < 1% in the first 5 years of use; risk rises with exposure and presence of comorbidities. The American Academy of Ophthalmology (AAO) screening guidelines for HCQ maculopathy recommend a baseline within the 1st year and, if normal, annual screening after 5 years. Patients are screened at baseline with a fundus examination at minimum and per the provider’s discretion may also undergo additional testing.

We evaluated our institutional screening practices and determined the cost of excess services provided and whether this practice led to an increase in detection of toxic maculopathy. We hypothesize that patients in our system are over screened, leading to waste.

Methods: All patients with an HCQ prescription in their medication list were included. Exclusions were: macular disease, single prior prescription, never-users or those with adverse effect with < 3 months of use, and those without appointments with rheumatology, ophthalmology or primary care within the institution. Electronic chart-based data collection included: weight-based dose of HCQ, duration of treatment (< 1, 1-5, or >5 years), tamoxifen use, history of kidney disease, and presence of toxic maculopathy. Screening recommendations were evaluated in compliance with the AAO recommendations for baseline and follow-up screening.

Results: 463 patients were prescribed HCQ between January 2010 and April 2020; 157 were included. HCQ use duration was distributed into 3 groups: < 1 year (n= 41), 1-5 years (n= 59), and >5 years (n= 57).

Of the 157 included patients, 38.7% underwent baseline ophthalmologic exam within one year of starting HCQ, 27.7% did not, and 33.6% had no documentation of a retinal exam. 33.6% of patients were inappropriately recommended to be screened again after baseline exam within 1 year.  Only 2% of patients were advised to rescreen following baseline exam after 5 years exposure per AAO guidelines. 9% of patients on HCQ for more than 5 years were appropriately receiving annual screening; 12.2% were not. All 3 cases of HCQ maculopathy in our system were diagnosed in appropriately screened patients. Over screening resulted in an additional $1853 per patient.

Conclusion: Our analysis of institutional screening practices for HCQ reveal that only 41% of patients are being appropriately screened. Contrary to our hypothesis, of the inappropriately screened patients, 29% were over screened and 71% were under screened. Of patients who had recorded follow-up recommendations after baseline exam, 94% were inappropriately recommended to follow up in 1 year, while only 6% were recommended to follow up after 5 years of HCQ use per AAO guidelines. Insurance demands regarding specialty care may be a cause of over screening as follow up visits greater than one year out require more administrative burden. Limitations to this study include inadequate available data and reliance on clinical documentation to establish screening methods. In those over screened, utilization costs were high, an additional $1853/patient. For those under screened, the health and financial consequences remain unknown.

Table 1: Demographics of included patients on hydroxychloroquine. CKD = Chronic Kidney Disease

Figure 1: Diagram of method of patient exclusion from study

Table 2: Screening practices and follow up recommendations for patients divided into length of time on hydroxychloroquine (HCQ)


Disclosure: A. James, None; K. Kam, None; V. Sandhu, GSK, 8; C. Downey, None.

To cite this abstract in AMA style:

James A, Kam K, Sandhu V, Downey C. Feast or Famine? An Institutional Assessment of Hydroxychloroquine Screening Practices [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/feast-or-famine-an-institutional-assessment-of-hydroxychloroquine-screening-practices/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/feast-or-famine-an-institutional-assessment-of-hydroxychloroquine-screening-practices/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology